Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial

Swerdlow, 2016, The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, 2375, 10.1182/blood-2016-01-643569 Campo, 2011, The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, 117, 5019, 10.1182/blood-2011-01-293050 Dana, 1993, Long-term follow-up of patients with low-grade malignant lymphoma treated with doxorubicin-based chemotherapy or chemoimmunotherapy, J Clin Oncol, 11, 644, 10.1200/JCO.1993.11.4.644 Hiddemann, 2005, Blood, 106, 3725, 10.1182/blood-2005-01-0016 Marcus, 2005, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma, Blood, 105, 1417, 10.1182/blood-2004-08-3175 Federico, 2013, R-CVP versus R-CHOP versus R-FM for initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi, J Clin Oncol, 31, 1506, 10.1200/JCO.2012.45.0866 Luminari, 2017, Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma, J Clin Oncol, 36, 689, 10.1200/JCO.2017.74.1652 Czuczman, 1999, Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy, J Clin Oncol, 17, 268, 10.1200/JCO.1999.17.1.268 Watanabe, 2011, Phase II/III study of R-CHOP-21 versus R-CHOP-14 for untreated indolent b-cell non-Hodgkin's lymphoma: JCOG0203 trial, J Clin Oncol, 29, 3990, 10.1200/JCO.2011.34.8508 Ozer, 2000, 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel, J Clin Oncol, 18, 3558, 10.1200/JCO.2000.18.20.3558 Hall, 1980, Confidence bands for a survival curve from censored data, Biometrika, 67, 133, 10.1093/biomet/67.1.133 Al-Tourah, 2008, Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma, J Clin Oncol, 26, 5165, 10.1200/JCO.2008.16.0283 Casulo, 2015, Transformed follicular non-Hodgkin lymphoma, Blood, 125, 40, 10.1182/blood-2014-04-516815 Montoto, 2007, Risk of clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma, J Clin Oncol, 25, 2426, 10.1200/JCO.2006.09.3260 Conconi, 2012, Incidence, risk factors and outcome of histologic transformation in follicular lymphoma, Br J Haematol, 157, 188, 10.1111/j.1365-2141.2012.09054.x Link, 2013, Rates and outcomes of follicular lymphoma transformation in the immunechemotherapy era: a report from the university of Iowa/Mayo clinic specialized program of research excellence molecular epidemiology resources, J Clin Oncol, 31, 3272, 10.1200/JCO.2012.48.3990 Sarcozy, 2016, Risk factors and outcomes for patients with follicular lymphoma who had histologic transformation after response to first-line immunochemotherapy in the PRIMA trial, J Clin Oncol, 34, 2575, 10.1200/JCO.2015.65.7163 Bachy, 2013, Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma, Haematologica, 98, 1107, 10.3324/haematol.2012.082412 Herold, 2015, Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma, J Cancer Res Clin Oncol, 141, 1689, 10.1007/s00432-015-1963-9 Salles, 2013, Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunechemotherapy, Blood, 122, 509, 10.1182/blood.V122.21.509.509 Flinn, 2014, Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study, Blood, 123, 2944, 10.1182/blood-2013-11-531327 Rummel, 2013, Bendamsutine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicenter, randomized, phase 3 non-inferiority trial, Lancet, 381, 1203, 10.1016/S0140-6736(12)61763-2 Salles, 2011, Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial, Lancet, 377, 42, 10.1016/S0140-6736(10)62175-7 Hiddemann, 2018, Immunotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: incidence of chemotherapy on efficacy and safety, J Clin Oncol, 36, 2395, 10.1200/JCO.2017.76.8960 Salles, 2017, Long term follow-up pf the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years, Blood, 130, 486 Magnano, 2017, Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial, Ann Hematol, 96, 639, 10.1007/s00277-017-2920-2 Sacci, 2008, Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: a 16-year follow-up study, Haematologica, 93, 398, 10.3324/haematol.12120 Carney, 2010, Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy, Leukemia, 24, 2056, 10.1038/leu.2010.218 Bennett, 2005, Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab, Blood, 105, 4576, 10.1182/blood-2004-12-4690 Rummel, 2017, Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study, J Clin Oncol, 35, 7501, 10.1200/JCO.2017.35.15_suppl.7501 Cheson, 1999, Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas, J Clin Oncol, 17, 1244, 10.1200/JCO.1999.17.4.1244 Casulo, 2015, Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study, J Clin Oncol, 33, 2516, 10.1200/JCO.2014.59.7534